Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes

Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes

Objective: Type 2 diabetic patients have a higher incidence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis, and nonalcoholic fatty liver disease (NAFLD) is associated with impaired bone health. We aimed to investigate whether bone turnover is associated with the probable pres...

Full description

Bibliographic Details
Main Authors:	Ningjian Wang, Yuying Wang, Xiaoman Chen, Wen Zhang, Yi Chen, Fangzhen Xia, Heng Wan, Qing Li, Boren Jiang, Bin Hu, Yingli Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-01-01
Series:	Frontiers in Endocrinology
Subjects:	type 2 diabetes mellitus nonalcoholic fatty liver disease advanced fibrosis nonalcoholic steatohepatitis bone turnover markers
Online Access:	https://www.frontiersin.org/article/10.3389/fendo.2019.00926/full

Similar Items

The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study
by: Ziteng Zhang, et al.
Published: (2022-12-01)

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
by: Georgiana-Emmanuela Gîlcă-Blanariu, et al.
Published: (2023-10-01)

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
by: Seonghwan Hwang, et al.
Published: (2021-10-01)

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in MiceSummary
by: Sadatsugu Sakane, et al.
Published: (2021-01-01)

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by: Reeju Amatya, et al.
Published: (2023-07-01)

Comparison of liver enzymes level and sonographic findings value with liver biopsy findings in nonalcoholic fatty liver disease patients
by: Mahsa Khodadoostan, et al.
Published: (2016-01-01)

Disease Progression in a Patient with Nonalcoholic Steatohepatitis
by: Ping-Huei Tseng, et al.
Published: (2008-10-01)

Recent update: Nonalcoholic steatohepatitis
by: Vivek Hande, et al.
Published: (2018-01-01)

Potential Hepatic Lipid Markers Associated with Nonalcoholic Steatohepatitis and Fibrosis in Morbid Obesity Patients
by: Hua-Chien Wu, et al.
Published: (2023-05-01)

Recent research trends and updates on nonalcoholic fatty liver disease
by: Jeong-Ju Yoo, et al.
Published: (2019-03-01)

Treatment Options in Non-alcoholic Fatty Liver Disease
by: Won Kim
Published: (2017-06-01)

Possible Development of Burn-Out Nonalcoholic Steatohepatitis under Long-Term Steroid Use
by: Soichiro Ota, et al.
Published: (2022-09-01)

Clinical and pathogenetic differences of the course of flow nonalcoholic steatohepatitis in obese patients with and without hypertension
by: O.S. Khukhlina, et al.
Published: (2013-08-01)

Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis
by: Stergios A. Polyzos, et al.
Published: (2020-09-01)

Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats
by: Wenhua Zhu, et al.
Published: (2017-09-01)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
by: Lucia Carulli, et al.
Published: (2019-02-01)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
by: Mindy C.W. Lam, et al.
Published: (2012-07-01)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
by: Apollinariya V. Bogolyubova, et al.
Published: (2017-12-01)

Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
by: In Cheol Yoon, et al.
Published: (2019-05-01)

Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet
by: Jiwon Choi, et al.
Published: (2023-08-01)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
by: Bing Yang, et al.
Published: (2022-09-01)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
by: Maria Sotiropoulou, et al.
Published: (2021-01-01)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
by: Hannah K. Drescher, et al.
Published: (2019-08-01)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
by: Bing Yang, et al.
Published: (2023-09-01)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
by: Takemi Akahane, et al.
Published: (2021-11-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
by: Gang Xu, et al.
Published: (2021-04-01)

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
by: Mohamed Salaheldin, et al.
Published: (2023-08-01)

Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis
by: Yaqiong Zhou, et al.
Published: (2017-09-01)

Prediction of course and progression of nonalcoholic fatty liver disease in patients with obesity and pathology of the biliary tract with the help of mathematical modeling.
by: A. Yu. Filippova, et al.
Published: (2017-12-01)

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
by: Jennifer Gallacher, et al.
Published: (2018-06-01)

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
by: Filip R, et al.
Published: (2018-10-01)

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
by: Umair Iqbal, et al.
Published: (2019-03-01)

Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: a randomized clinical trial
by: Thushara Rodrigo, et al.
Published: (2022-06-01)

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2020-12-01)

Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis
by: S.M. Touhidul Islam, et al.
Published: (2020-09-01)

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
by: Ho Soo Chun, et al.
Published: (2023-04-01)

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
by: Seonghwan Hwang, et al.
Published: (2022-07-01)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
by: Hirokazu Takahashi, et al.
Published: (2023-04-01)